Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer

NCT05309629 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive-stage Small-cell Lung Cancer

Interventions

DRUG: QL1706
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

Qilu Pharmaceutical Co., Ltd.